Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium

Our portfolio company Juvabis AG announces the completion and positive results from its first-in-human single intravenous dose Phase 1 study in healthy volunteers. EBL-1003 (apramycin) was safe and well-tolerated in all dose groups. The results support further clinical development of EBL-1003 in patients.


Juvabis AG is a clinical-stage biopharmaceutical company focused on discovering and developing treatments in high unmet medical needs involving multidrug-resistant bacterial infections. The randomized, double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of single intravenous doses in healthy volunteers. Read their press release here:




HEMEX is committed to changing the future of healthcare by guiding the most promising European start-ups through each and every step to bring innovative pharmaceuticals, medical devices and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure start-ups have access to a wide range of tailored products, practical solutions and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare. For more information, visit https://hemex.ch/

Leave a Reply

Your email address will not be published. Required fields are marked *